Log In Sign up
The largest database of trusted experimental protocols
> Chemicals & Drugs > Organic Chemical > Clodronate

Clodronate

Clodronate is a bisphosphonate medication used to treat conditions involving excessive bone resorption, such as Paget's disease of bone, hypercalcemia of malignancy, and osteoporosis.
It functions by inhibiting osteoclast activity and promoting osteoclast apoptosis, thereby reducing bone resorption.
Clodronate may also have antitumor effects and has been investigated for use in various cancers.
Researchers can utilize PubCompare.ai's powerful tools to optimize their Clodronate research, locating relevant protocols from literature, preprints, and patents, and using AI-driven comparisons to identify the best approaches.
This can enhance reproducibility and accuracy, allowing researchers to fully explore the potential of Clodronate in their studies.

Most cited protocols related to «Clodronate»

1
Mobilizing Hematopoietic Stem Cells
Cited 20 times

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2013
AMD 3100 Biological Assay BLOOD Cells Chemokine Clodronate Flow Cytometry GW 3965 Immunofluorescence Liposomes Mice, House Saline Solution Sulfoxide, Dimethyl Tissues
2
Dissecting Antiviral Immune Responses in Mice
Cited 15 times
C57BL/6, BALB/c, CD11c-DTR GFP19 (link), Tg720 (link), DPE-GFP21 (link), and IFNαβR−/−9 mice were used. VSV, serotypes Indiana (Mudd-Summers derived clone, in vitro rescued22 (link) and plaque purified), New Jersey (Pringle Isolate, plaque purified), and VSV-eGFP11 (link) were propagated on BSRT7 cells, and purified as described2 (link). LN macrophages were depleted by injections in the footpad or in the calf of clodronate liposomes (CLL23 (link)) or diphtheria toxin 6 days or 60 days prior to infection. In other experiments pDCs were depleted by intravenous injection of anti-PDCA-1 MAb 24h prior to infection. VSV titers from organs of infected mice were determined by plaque assay on Vero cells. Serum of infected or control mice was assessed for the presence of neutralizing antibody titers as described2 (link). After footpad infection, draining popliteal LNs were harvested for whole mount immunofluorescence multiphoton microscopy analysis, for flow cytometry analysis, or to generate frozen sections for immunostaining and confocal microscopy. LN protein extracts and supernatants from sorted VSV-infected cells were assayed for IFNα using an IFNα ELISA kit (PBL InterferonSource). For sciatic nerve resection, the nerve was exposed through an incision on the lateral aspect of the mid thigh, resected and the distal and proximal nerve stumps were separately tucked into adjacent intermuscular spaces to prevent nerve regeneration. Results are expressed as mean ± s.e.m. Means between two groups were compared using two-tailed t-test. Means among three or more groups were compared using one-way analysis of variance with Bonferroni’s post-test. Kaplan-Meier survival curves were compared using the Log-rank (Mantel-Cox) test.
Iannacone M., Moseman E.A., Tonti E., Bosurgi L., Junt T., Henrickson S.E., Whelan S.P., Guidotti L.G, & von Andrian U.H. (2010). Subcapsular Sinus Macrophages Prevent CNS Invasion Upon Peripheral Infection With a Neurotropic Virus. Nature, 465(7301), 1079-1083.
Publication 2010
Amputation Stumps Antibodies, Neutralizing BST2 protein, human Cells Clodronate Clone Cells Dental Plaque Diphtheria Toxin Enzyme-Linked Immunosorbent Assay Flow Cytometry Frozen Sections Immunofluorescence Microscopy Infection Interferon-alpha Liposomes Macrophage Microscopy, Confocal Mus Nerve Regeneration Nervousness Neurectomy PDC protein, human Proteins Serum Thigh Vero Cells
3
Dissecting Antiviral Immune Responses in Mice
Cited 15 times
C57BL/6, BALB/c, CD11c-DTR GFP19 (link), Tg720 (link), DPE-GFP21 (link), and IFNαβR−/−9 mice were used. VSV, serotypes Indiana (Mudd-Summers derived clone, in vitro rescued22 (link) and plaque purified), New Jersey (Pringle Isolate, plaque purified), and VSV-eGFP11 (link) were propagated on BSRT7 cells, and purified as described2 (link). LN macrophages were depleted by injections in the footpad or in the calf of clodronate liposomes (CLL23 (link)) or diphtheria toxin 6 days or 60 days prior to infection. In other experiments pDCs were depleted by intravenous injection of anti-PDCA-1 MAb 24h prior to infection. VSV titers from organs of infected mice were determined by plaque assay on Vero cells. Serum of infected or control mice was assessed for the presence of neutralizing antibody titers as described2 (link). After footpad infection, draining popliteal LNs were harvested for whole mount immunofluorescence multiphoton microscopy analysis, for flow cytometry analysis, or to generate frozen sections for immunostaining and confocal microscopy. LN protein extracts and supernatants from sorted VSV-infected cells were assayed for IFNα using an IFNα ELISA kit (PBL InterferonSource). For sciatic nerve resection, the nerve was exposed through an incision on the lateral aspect of the mid thigh, resected and the distal and proximal nerve stumps were separately tucked into adjacent intermuscular spaces to prevent nerve regeneration. Results are expressed as mean ± s.e.m. Means between two groups were compared using two-tailed t-test. Means among three or more groups were compared using one-way analysis of variance with Bonferroni’s post-test. Kaplan-Meier survival curves were compared using the Log-rank (Mantel-Cox) test.
Iannacone M., Moseman E.A., Tonti E., Bosurgi L., Junt T., Henrickson S.E., Whelan S.P., Guidotti L.G, & von Andrian U.H. (2010). Subcapsular Sinus Macrophages Prevent CNS Invasion Upon Peripheral Infection With a Neurotropic Virus. Nature, 465(7301), 1079-1083.
Publication 2010
Amputation Stumps Antibodies, Neutralizing BST2 protein, human Cells Clodronate Clone Cells Dental Plaque Diphtheria Toxin Enzyme-Linked Immunosorbent Assay Flow Cytometry Frozen Sections Immunofluorescence Microscopy Infection Interferon-alpha Liposomes Macrophage Microscopy, Confocal Mus Nerve Regeneration Nervousness Neurectomy PDC protein, human Proteins Serum Thigh Vero Cells
4
Labeling Gr-1 Monocyte Subsets
Cited 12 times
0.5-μm FITC-conjugated (yellow gold) plain microspheres (2.5% solids [wt/vol]; Polysciences, Inc.) were diluted 1:25 in PBS, and 250 μl of the solution was injected into the lateral tail vein for labeling of Gr-1lo monocytes. For labeling of Gr-1hi monocytes, 250 μl of liposomes containing clodronate were i.v. injected followed by 250 μl of fluorescent microspheres i.v. 16–18 h later. Clodronate was a gift from Roche and was incorporated into liposomes as previously described (27 (link)). We used the dose of CLL shown to fully eliminate blood monocytes (26 (link)); this method, with the introduction of CLL i.v., will also eliminate splenic and liver macrophages (27 (link)). Other macrophage populations are protected because CLL will not cross vascular barriers (27 (link)). In some experiments, red fluorescent (580-nm excitation wavelength and 605-nm emission wavelength) carboxylate-modified 0.5-μm microspheres (2.0% solids [wt/vol]; Invitrogen) were used and conjugated to OVA (Sigma-Aldrich). Coupling of OVA to these particles was performed using the Carbodiimide Kit from Polysciences, Inc.
Tacke F., Ginhoux F., Jakubzick C., van Rooijen N., Merad M, & Randolph G.J. (2006). Immature monocytes acquire antigens from other cells in the bone marrow and present them to T cells after maturing in the periphery. The Journal of Experimental Medicine, 203(3), 583-597.
Publication 2006
Blood Vessel Carbodiimides Clodronate Fluorescein-5-isothiocyanate Gold Kupffer Cells Liposomes Macrophage Microspheres Monocytes Population Group Spleen Tail Veins
5
Corneal Transfection and Immune Cell Depletion
Cited 12 times
Neutralizing goat antibody (10 μg) against mouse flt-1 (R&D Systems), isotype control goat IgG (10 μg; Jackson Immunoresearch), shRNAs (4 μg) against mbflt-1 or sflt-1, psflt-1 (4 μg), psflt-1* (4 μg), pCre (4 μg; gift of R.K. Nordeen, University of Colorado), pNull (4 μg), rmVEGF-A164 (20–500 ng; R&D Systems), sflt-1/Fc (5 μg; R&D Systems), or isotype control IgG1/Fc (5 μg; Jackson Immunoresearch) were injected (2 μl) into the cornea with a 33-gauge needle, as previously reported18 (link). The efficiency of corneal transfection by naked plasmid of pGFP (gift of X. Li, University of Kentucky) or placZ (gift of B.T. Spear, University of Kentucky) exceeded 70%, as gauged by flow cytometry and X-gal staining (Supplementary Fig. 11). We performed tail-vein injection of clodronate liposomes (200 μl) and intraperitoneal injection of anti-Gr-1 antibodies (200 μg; eBioscience) on each of the two days before and after corneal injection of pshRNA–sflt-1 to deplete peripheral monocytes/macrophages and neutrophils.
Ambati B.K., Nozaki M., Singh N., Takeda A., Jani P.D., Suthar T., Albuquerque R.J., Richter E., Sakurai E., Newcomb M.T., Kleinman M.E., Caldwell R.B., Lin Q., Ogura Y., Orecchia A., Samuelson D.A., Agnew D.W., Leger J.S., Green W.R., Mahasreshti P.J., Curiel D.T., Kwan D., Marsh H., Ikeda S., Leiper L.J., Collinson J.M., Bogdanovich S., Khurana T.S., Shibuya M., Baldwin M.E., Ferrara N., Gerber H.P., Falco S.D., Witta J., Baffi J.Z., Raisler B.J, & Ambati J. (2006). Corneal avascularity is due to soluble VEGF receptor-1. Nature, 443(7114), 993-997.
Publication 2006
5-bromo-4-chloro-3-indolyl beta-galactoside Antibodies, Neutralizing Clodronate Cornea Flow Cytometry FLT1 protein, human Goat IgG1 Immunoglobulin Isotypes Liposomes Macrophage Mus Needles Neutrophil Passive Immunization PBMC Peripheral Blood Mononuclear Cells Plasmids Short Hairpin RNA Tail Transfection Veins

Most recents protocols related to «Clodronate»

1
Macrophage Depletion for E. coli Infection

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2023
Clodronate Escherichia coli Flow Cytometry Liposomes Macrophage Mus
2
Tumor Growth Inhibition via Immunomodulation
C57BL/6 mice were maintained in an animal facility under pathogen-free conditions. After acclimatization, a total of 2 × 105 LLC cells were subcutaneously injected into the right flank of the mice. Tumor dimensions were measured with calipers every 3 days and the tumor volumes (mm3) were calculated by applying the following formula: (length × width2)/2. ADNVs (25 mg/kg), alone or with αPD-L1 antibody (10 mg/kg) (Bio-XCell, BP0101), were instilled at day 7 after tumor cell inoculation, every 3 days for 2 weeks. To deplete TAMs in tumor, LLC tumor-bearing mice were treated with clodronate liposomes (CL, Yeasen, 40337ES08) at 200 μg per mouse every 4 days by intraperitoneal injection. Mice in the control group were treated with the same dose of liposomes containing PBS (PL, Yeasen, 40338ES05). On the indicated days after inoculation, mice were sacrificed, and the tissues were collected for analysis.
Liu J., Xiang J., Jin C., Ye L., Wang L., Gao Y., Lv N., Zhang J., You F., Qiao H, & Shi L. (2023). Medicinal plant-derived mtDNA via nanovesicles induces the cGAS-STING pathway to remold tumor-associated macrophages for tumor regression. Journal of Nanobiotechnology, 21, 78.
Full text: Click here
Publication 2023
Acclimatization Animals Cancer Vaccines Cells Clodronate Immunoglobulins Injections, Intraperitoneal Liposomes Mice, Inbred C57BL Mus Myeloproliferative Syndrome, Transient Neoplasms pathogenesis Tissues Vaccination
3
Immunotherapy for Obesity-Associated HCC
The animal research protocol was approved by the ethical committee at the University of Geneva and the Geneva veterinary authorities (GE195/19 and GE71). All mice were housed in the animal facility of the University of Geneva on 12/12-hour light/dark cycles with free access to food and water. C57BL/6 N were purchased from Charles River Laboratories (Ecully, France) and were fed a control diet (ND: 17% kcal fat, 61% kcal carbohydrate, 22% kcal protein; Envigo TD.120455) or a high fat/high sucrose diet (HFD: 45% kcal fat, 41% kcal carbohydrate, 15% kcal protein; Envigo TD.08811) for 30 weeks. Mice underwent laparotomy and 1.5.105 RIL-175-LV-OVA-GFP or 4. 105 MC-38 cells were injected into the portal vein. One group of HFD-fed mice was injected with 100 µg of anti-CD122 antibody per mouse (intraperitoneal, 5H4, BioXcell) every third day starting on day 12 after HCC injection. The control group was injected with rat IgG2a. For CD8+ cells depletion, mice were injected with 150 µg of anti-CD8a per mouse (intraperitoneal, 53–6.7, BioXcell) every third day starting on day 12 after HCC injection. For macrophages and dendritic cells depletion, HFD-fed mice were injected with clodronate liposomes (intraperitoneal, Liposoma) every four days starting on day 8 after HCC injection. PBS liposomes were injected as control.
Lacotte S., Slits F., Moeckli B., Peloso A., Koenig S., Tihy M., El Hajji S., Gex Q., Rubbia-Brandt L, & Toso C. (2023). Anti-CD122 antibody restores specific CD8+ T cell response in nonalcoholic steatohepatitis and prevents hepatocellular carcinoma growth. Oncoimmunology, 12(1), 2184991.
Publication 2023
Animals Antibodies, Anti-Idiotypic Carbohydrates CD8-Positive T-Lymphocytes Cells Clodronate Dendritic Cells Diet, High-Fat Food IgG2A IL2RB protein, human Laparotomy Liposomes Macrophage Mus Proteins Rivers Sucrose Therapy, Diet Veins, Portal
4
Depletion and Reconstitution of Macrophages
Clodronate-containing liposomes were used to eliminate macrophages in terms of published investigations46 (link). Briefly, mice were injected with one dose of 5 mg/ml clodronate-liposomes (0.2 ml/mouse, Encapsula NanoSciences, Cat#: CLD-8901) intravenously. After 48 hrs, depletion of macrophages was confirmed by MACS. Two days after this depletion treatment, mice were reconstituted by intravenous injection with 2 × 106 mouse-derived differentiated BMDMs which were dissolved in PBS. In other experiments, mice were reconstituted with lentivirus-transduced BMDMs. After 36 h, these reconstituted mice were intraperitoneally injected with PBS (pH7.0) or LPS (20 mg/kg) and monitored closely for up to 96 h.
Wang X., Ding Y., Li R., Zhang R., Ge X., Gao R., Wang M., Huang Y., Zhang F., Zhao B., Liao W, & Du J. (2023). N6-methyladenosine of Spi2a attenuates inflammation and sepsis-associated myocardial dysfunction in mice. Nature Communications, 14, 1185.
Full text: Click here
Publication 2023
Clodronate Lentivirus Liposomes Macrophage Mus
5
Clodronate Liposome Injection Protocol
Twenty microliters of 10 mg ml−1 clodronate liposomes or control liposomes were subcutaneously injected into the right side of the hind paw skin on days 0 and 3.
Tanaka T., Okuda H., Isonishi A., Terada Y., Kitabatake M., Shinjo T., Nishimura K., Takemura S., Furue H., Ito T., Tatsumi K, & Wanaka A. (2023). Dermal macrophages set pain sensitivity by modulating the amount of tissue NGF through an SNX25–Nrf2 pathway. Nature Immunology, 24(3), 439-451.
Full text: Click here
Publication 2023
Clodronate Liposomes Skin

Top products related to «Clodronate»

1
Clodronate liposome by Liposoma
Sourced in Netherlands
Clodronate liposomes are a laboratory product consisting of the bisphosphonate compound clodronate encapsulated within liposome vesicles. The core function of clodronate liposomes is to serve as a tool for selectively depleting or modulating macrophage populations in experimental research settings.
2
Clodronate liposome by Encapsula Nanosciences
Sourced in United States
Clodronate liposomes are a type of lab equipment used in research. They are lipid-based carriers that can encapsulate the drug clodronate. Clodronate liposomes are used to deliver clodronate to target cells or tissues in experimental settings.
3
Clodronate by Merck Group
Sourced in United States
Clodronate is a lab equipment product manufactured by the Merck Group. It is a bisphosphonate compound used in various research and scientific applications. The core function of Clodronate is to serve as a reagent or analytical tool in laboratory settings, without any interpretation or extrapolation on its intended use.
4
Clodronate liposome by Formumax Scientific
Sourced in United States
Clodronate liposomes are a type of liposome formulation that contains the bisphosphonate compound clodronate. Liposomes are microscopic vesicles composed of a phospholipid bilayer membrane that can be used to encapsulate and deliver various substances. The clodronate compound is encapsulated within the liposomes, which can be used for experimental research purposes.
5
Clodronate liposome by Yeasen
Sourced in China
Clodronate liposomes are a type of lab equipment used for the encapsulation and delivery of the drug clodronate. They serve as a tool for research purposes, allowing for the controlled administration and study of clodronate in various experimental settings.
6
Clodrosome by Encapsula Nanosciences
Sourced in United States
Clodrosome is a laboratory instrument designed for the encapsulation of materials within liposomal structures. It utilizes a proprietary process to efficiently entrap substances within lipid-based vesicles. The core function of the Clodrosome is to facilitate the preparation of liposome samples for various research and analytical applications.
7
Control liposome by Formumax Scientific
Sourced in United States
Control liposome is a laboratory-grade lipid vesicle used to establish baseline measurements and validate experimental protocols. It serves as a reference standard to ensure the reliability and consistency of liposome-based research and applications.
8
Clodronate by Encapsula Nanosciences
Sourced in United States
Clodronate is an inorganic compound that is used as a laboratory reagent. It is a bisphosphonate compound that inhibits bone resorption. Clodronate is commonly used in research settings to deplete macrophages and study their role in various biological processes.
9
Clodronate by Liposoma
Sourced in Netherlands
Clodronate is a pharmaceutical compound used in the development and production of various laboratory equipment. It functions as a bisphosphonate, a class of drugs that inhibit bone resorption. Clodronate is commonly utilized in the research and manufacturing of products related to bone metabolism and related medical applications.
10
Lipopolysaccharides (lps) by Merck Group
Sourced in United States, Germany, China, United Kingdom, Sao Tome and Principe, Macao, Italy, Japan, Canada, France, Switzerland, Israel, Australia, Spain, India, Ireland, Brazil, Poland, Netherlands, Sweden, Denmark, Hungary, Austria, Mongolia
The LPS laboratory equipment is a high-precision device used for various applications in scientific research and laboratory settings. It is designed to accurately measure and monitor specific parameters essential for various experimental procedures. The core function of the LPS is to provide reliable and consistent data collection, ensuring the integrity of research results. No further details or interpretations can be provided while maintaining an unbiased and factual approach.

More about "Clodronate"

Clodronate, also known as Clodrosome or Clodronate liposomes, is a bisphosphonate medication used to treat various conditions involving excessive bone resorption, such as Paget's disease of bone, hypercalcemia of malignancy, and osteoporosis.
This drug functions by inhibiting osteoclast activity and promoting osteoclast apoptosis, thereby reducing bone resorption.
Clodronate has also been investigated for its potential antitumor effects and has been studied for use in various cancers.
Researchers can utilize PubCompare.ai's powerful tools to optimize their Clodronate research, locating relevant protocols from literature, preprints, and patents, and using AI-driven comparisons to identify the best approaches.
This can enhance reproducibility and accuracy, allowing researchers to fully explore the potnetial of Clodronate in their studies.
PubCompare.ai's tools can help researchers discover new applications and formulations of Clodronate, such as Clodronate liposomes, which may offer enhanced delivery and targeting capabilities.
By leveraging the insights gained from the MeSH term description and the powerful comparison features of PubCompare.ai, researchers can navigate the landscape of Clodronate research more effectively, leading to breakthroughs in the treatment of bone-related disorders and cancer.